CalciMedica (CALC) Misses Q2 EPS by 36c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Marvell shares jump after giving Google warrants amid custom chip deal
Oppenheimer Reiterates Outperform Rating on CalciMedica (CALC)
August 14, 2024 6:48 AM EDTOppenheimer analyst Leland Gershall reiterated an Outperform rating and $20.00 price target on CalciMedica (NASDAQ: CALC)
The analyst comments "CALC reported on its development progress with CRAC channel inhibitor Auxora. Following the positive Phase 2b CARPO reveal in acute pancreatitis (AP) reported... More
